GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof
AssigneeCrage Medical Co., Limited
InventorsHuamao Wang, Xiumei Cai, Hongxia Zhao, Bo Song, Yuanmei Chen, Yinyu Zhu
Life of this patent
Estimating the term…
Abstract
Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.
Claims11
A double-targeted chimeric antigen receptor immune effector cell, wherein the cell expresses the following chimeric receptors:
- a chimeric antigen receptor specifically recognizing Glypican-3 (GPC3);
- and
- a chimeric antigen receptor specifically recognizing Asialoglycoprotein receptor (ASGPR1);
- wherein the chimeric antigen receptor specifically recognizing GPC3 comprises:
- an anti-GPC3 single chain antibody, and one or more T cell stimulatory signaling molecules;
- and
- the chimeric costimulatory receptor specifically recognizing ASGPR1 comprises:
- an anti-ASGPR1 single chain antibody, and a T cell activated co-stimulatory signaling molecule.
A double-targeted chimeric antigen receptor immune effector cell, wherein the cell expresses the following chimeric receptors:
- a chimeric antigen receptor specifically recognizing Glypican-3 (GPC3) comprising an anti-GPC3 single chain antibody, a transmembrane region of CD8, and CD3ζ;
- and
- a chimeric antigen receptor specifically recognizing Asialoglycoprotein receptor (ASGPR1) consisting essentially of an anti ASGPR1 single chain antibody, a transmembrane region of CD28, an intracellular signaling region of a CD28 protein, and an intracellular signaling region of a CD137 protein.
Dependencies are inferred from the claim text.